Literature DB >> 24989113

Association of CYP1B1 Leu432Val polymorphism and lung cancer risk: an updated meta-analysis.

Xianjun Lao1, Xue Qin, Qiliu Peng, Zhiping Chen, Yu Lu, Yanqiong Liu, Shan Li.   

Abstract

BACKGROUND: Cytochrome P4501B1 (CYP1B1) a phase I enzyme, is involved in the activation of a broad spectrum of procarcinogens. Impacts on the catalytic activity of the CYP1B1 enzyme, as well as an association of the Leu432Val polymorphism with the risk of lung cancer, have been described; however, the results remain controversial.
METHODS: We conducted a meta-analysis of all available studies to clarify the effects of the Leu432Val polymorphism on lung cancer risks basing on 2,543 lung cancer cases and 3,304 controls from ten separate comparisons. We also performed subgroup analyses by ethnicity (categorized as Caucasian, Asian and African-American), gender, smoking status ,and histological type. A pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to estimate the strength of the association.
RESULTS: A significantly increased risk was found in our meta-analysis in the overall population (Val/Val vs. Leu/Leu: OR = 1.371, 95% CI 1.137-1.652, P = 0.001). In subgroup analysis, significant associations with lung cancer susceptibility were also found in Caucasians (Val/Val vs. Leu/Leu: OR = 1.312, 95% CI 1.075-1.602, P = 0.008), females (Val/Val vs. Leu/Leu: OR = 1.472, 95% CI 1.097-1.976, P = 0.010), and smokers (dominant model Leu/Val + Val/Val vs. Leu/Leu: OR = 1.257, 95% CI 1.016-1.554, P = 0.035). Null results were noted in the subgroup analysis by histological type under different genetic models.
CONCLUSIONS: Our results suggest that the CYP1B1 Leu432Val polymorphism acts as a risk factor for the carcinogenesis of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24989113     DOI: 10.1007/s00408-014-9618-1

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  38 in total

1.  Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue.

Authors:  Y Ko; J Abel; V Harth; P Bröde; C Antony; S Donat; H P Fischer; M E Ortiz-Pallardo; R Thier; A Sachinidis; H Vetter; H M Bolt; C Herberhold; T Brüning
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer.

Authors:  J Watanabe; T Shimada; E M Gillam; T Ikuta; K Suemasu; Y Higashi; O Gotoh; K Kawajiri
Journal:  Pharmacogenetics       Date:  2000-02

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer.

Authors:  Mette Sørensen; Herman Autrup; Anne Tjønneland; Kim Overvad; Ole Raaschou-Nielsen
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

6.  Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure.

Authors:  B Schoket; G Papp; K Lévay; G Mracková; F F Kadlubar; I Vincze
Journal:  Mutat Res       Date:  2001-10-01       Impact factor: 2.433

7.  Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population.

Authors:  Geyu Liang; Yuepu Pu; Lihong Yin
Journal:  Cancer Lett       Date:  2005-06-08       Impact factor: 8.679

Review 8.  The changing epidemiology of lung cancer in Europe.

Authors:  Maryska L G Janssen-Heijnen; Jan-Willem W Coebergh
Journal:  Lung Cancer       Date:  2003-09       Impact factor: 5.705

9.  CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences.

Authors:  Maria N Timofeeva; Silke Kropp; Wiebke Sauter; Lars Beckmann; Albert Rosenberger; Thomas Illig; Birgit Jäger; Kirstin Mittelstrass; Hendrik Dienemann; Helmut Bartsch; Heike Bickeböller; Jenny C Chang-Claude; Angela Risch; Heinz-Erich Wichmann
Journal:  Carcinogenesis       Date:  2009-05-04       Impact factor: 4.944

10.  A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Authors:  Shanbeh Zienolddiny; Daniele Campa; Helge Lind; David Ryberg; Vidar Skaug; Lodve B Stangeland; Federico Canzian; Aage Haugen
Journal:  Carcinogenesis       Date:  2008-02-06       Impact factor: 4.944

View more
  4 in total

Review 1.  Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms.

Authors:  Mengsi Hu; Qianhui Wang; Bing Liu; Qiqi Ma; Tingwei Zhang; Tongtong Huang; Zhimei Lv; Rong Wang
Journal:  Front Cell Dev Biol       Date:  2022-05-18

2.  Impact of CYP1A1 Polymorphisms on Susceptibility to Chronic Obstructive Pulmonary Disease: A Meta-Analysis.

Authors:  Cheng-Di Wang; Nan Chen; Lin Huang; Jia-Rong Wang; Zhi-Yuan Chen; Ya-Mei Jiang; Ya-Zhou He; Yu-Lin Ji
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411

Review 3.  Are healthy smokers really healthy?

Authors:  Zijing Zhou; Ping Chen; Hong Peng
Journal:  Tob Induc Dis       Date:  2016-11-15       Impact factor: 2.600

Review 4.  Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer.

Authors:  Rachel Stading; Grady Gastelum; Chun Chu; Weiwu Jiang; Bhagavatula Moorthy
Journal:  Semin Cancer Biol       Date:  2021-07-07       Impact factor: 15.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.